Log Type Authored on Log Message Log Node Authored by
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E7%B5%B1%E5%90%88%E5%A4%B1%E8%AA%BF%E7%97%87%E6%82%A3%E8%80%85%E3%81%AE%E5%86%8D%E7%99%BA%E5%B1%A5%E6%AD%B4%E3%81%AB%E5%9F%BA%E3%81%A5%E3%81%8F%E5%86%8D%E7%99%BA%E6%99%82%E6%9C%9F%E3%81%AE%E4%BA%88%E6%B8%AC Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E6%85%A2%E6%80%A7%E7%9A%84%E3%83%BB%E9%87%8D%E7%AF%A4%E3%81%AA%E5%AD%A4%E7%8B%AC%E6%84%9F%E3%82%92%E6%9C%89%E3%81%99%E3%82%8B%E5%89%B2%E5%90%88%E3%81%AB%E5%9B%BD%E3%83%BB%E5%9C%B0%E5%9F%9F%E9%96%93%E3%81%A7%E5%B7 Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E6%85%A2%E6%80%A7%E7%9A%84%E3%83%BB%E9%87%8D%E7%AF%A4%E3%81%AA%E5%AD%A4%E7%8B%AC%E6%84%9F%E3%82%92%E6%9C%89%E3%81%99%E3%82%8B%E5%89%B2%E5%90%88%E3%81%AB%E5%9B%BD%E3%83%BB%E5%9C%B0%E5%9F%9F%E9%96%93%E3%81%A7%E5%B7 Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/icu%E3%81%A7%E6%AD%BB%E4%BA%A1%E3%81%99%E3%82%8B%E6%82%A3%E8%80%85%E3%81%AE%E5%AE%B6%E6%97%8F%E3%81%AB%E3%81%AF%E3%80%8C3%E6%AE%B5%E9%9A%8E%E3%82%B5%E3%83%9D%E3%83%BC%E3%83%88%E6%96%B9%E5%BC%8F%E3%80%8D%E3%81%8C%E Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/icu%E3%81%A7%E6%AD%BB%E4%BA%A1%E3%81%99%E3%82%8B%E6%82%A3%E8%80%85%E3%81%AE%E5%AE%B6%E6%97%8F%E3%81%AB%E3%81%AF%E3%80%8C3%E6%AE%B5%E9%9A%8E%E3%82%B5%E3%83%9D%E3%83%BC%E3%83%88%E6%96%B9%E5%BC%8F%E3%80%8D%E3%81%8C%E Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E7%AC%A0%E5%8E%9F-%E5%98%89-%E5%85%88%E7%94%9F%E3%81%AB%E3%82%88%E3%82%8B%E6%9C%80%E7%B5%82%E8%AC%9B%E7%BE%A9%EF%BC%88%E5%85%A87%E5%9B%9E%EF%BC%89 Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E7%AC%A0%E5%8E%9F-%E5%98%89-%E5%85%88%E7%94%9F%E3%81%AB%E3%82%88%E3%82%8B%E6%9C%80%E7%B5%82%E8%AC%9B%E7%BE%A9%EF%BC%88%E5%85%A87%E5%9B%9E%EF%BC%89 Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E8%84%B3%E5%86%85%E7%82%8E%E7%97%87%E3%81%A8%E7%B2%BE%E7%A5%9E%E7%96%BE%E6%82%A3%EF%BD%9E%E3%81%86%E3%81%A4%E7%97%85%E3%82%92%E4%B8%AD%E5%BF%83%E3%81%AB%EF%BD%9E%E3%80%80%E7%B2%BE%E7%A5%9E%E5%8C%BB%E5%AD%A6%E3%82 Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E8%84%B3%E5%86%85%E7%82%8E%E7%97%87%E3%81%A8%E7%B2%BE%E7%A5%9E%E7%96%BE%E6%82%A3%EF%BD%9E%E3%81%86%E3%81%A4%E7%97%85%E3%82%92%E4%B8%AD%E5%BF%83%E3%81%AB%EF%BD%9E%E3%80%80%E7%B2%BE%E7%A5%9E%E5%8C%BB%E5%AD%A6%E3%82 Anonimnež
Newsletter opened Opened Anonimnež
Newsletter opened Opened Anonimnež
Newsletter sent Newsletter Test sent to:AYTK@lundbeck.com Anonimnež
Newsletter opened Opened Anonimnež
Newsletter sent Newsletter Test sent to:AYTK@lundbeck.com Anonimnež
Newsletter opened Opened Anonimnež
Newsletter opened Opened Anonimnež
Newsletter opened Opened Anonimnež
Newsletter clicked Clicked https://brazil.progress.im/pt-br/content/novos-medicamentos-com-anticorpos-monoclonais-t%C3%AAm-como-alvo-cgrp-e-seus-receptores Novos medicamentos têm como alvo a CGRP e seus receptores Anonimnež
Newsletter opened Opened Atualize-se com a Progress in Mind Brazil Anonimnež
Newsletter opened Opened Apoio à saúde mental em tempos de crise Anonimnež
Newsletter opened Opened Novos medicamentos têm como alvo a CGRP e seus receptores Anonimnež
Newsletter opened Opened A disfunção sináptica como fator fisiopatológico chave na esquizofrenia Anonimnež
Newsletter opened Opened Highlight CINP 2021 | O conceito de "engajamento com a vida" como meta de tratamento na esquizofrenia Anonimnež
Newsletter opened Opened Convite Masterclass em Transtorno Depressivo Maior - Webinar Internacional Anonimnež
Newsletter opened Opened Convite Masterclass em Transtorno Depressivo Maior - Webinar Internacional Anonimnež
Log Type Authored on Log Message Log Node Authored by
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E7%B5%B1%E5%90%88%E5%A4%B1%E8%AA%BF%E7%97%87%E6%82%A3%E8%80%85%E3%81%AE%E5%86%8D%E7%99%BA%E5%B1%A5%E6%AD%B4%E3%81%AB%E5%9F%BA%E3%81%A5%E3%81%8F%E5%86%8D%E7%99%BA%E6%99%82%E6%9C%9F%E3%81%AE%E4%BA%88%E6%B8%AC Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E6%85%A2%E6%80%A7%E7%9A%84%E3%83%BB%E9%87%8D%E7%AF%A4%E3%81%AA%E5%AD%A4%E7%8B%AC%E6%84%9F%E3%82%92%E6%9C%89%E3%81%99%E3%82%8B%E5%89%B2%E5%90%88%E3%81%AB%E5%9B%BD%E3%83%BB%E5%9C%B0%E5%9F%9F%E9%96%93%E3%81%A7%E5%B7 Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E6%85%A2%E6%80%A7%E7%9A%84%E3%83%BB%E9%87%8D%E7%AF%A4%E3%81%AA%E5%AD%A4%E7%8B%AC%E6%84%9F%E3%82%92%E6%9C%89%E3%81%99%E3%82%8B%E5%89%B2%E5%90%88%E3%81%AB%E5%9B%BD%E3%83%BB%E5%9C%B0%E5%9F%9F%E9%96%93%E3%81%A7%E5%B7 Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/icu%E3%81%A7%E6%AD%BB%E4%BA%A1%E3%81%99%E3%82%8B%E6%82%A3%E8%80%85%E3%81%AE%E5%AE%B6%E6%97%8F%E3%81%AB%E3%81%AF%E3%80%8C3%E6%AE%B5%E9%9A%8E%E3%82%B5%E3%83%9D%E3%83%BC%E3%83%88%E6%96%B9%E5%BC%8F%E3%80%8D%E3%81%8C%E Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/icu%E3%81%A7%E6%AD%BB%E4%BA%A1%E3%81%99%E3%82%8B%E6%82%A3%E8%80%85%E3%81%AE%E5%AE%B6%E6%97%8F%E3%81%AB%E3%81%AF%E3%80%8C3%E6%AE%B5%E9%9A%8E%E3%82%B5%E3%83%9D%E3%83%BC%E3%83%88%E6%96%B9%E5%BC%8F%E3%80%8D%E3%81%8C%E Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E7%AC%A0%E5%8E%9F-%E5%98%89-%E5%85%88%E7%94%9F%E3%81%AB%E3%82%88%E3%82%8B%E6%9C%80%E7%B5%82%E8%AC%9B%E7%BE%A9%EF%BC%88%E5%85%A87%E5%9B%9E%EF%BC%89 Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E7%AC%A0%E5%8E%9F-%E5%98%89-%E5%85%88%E7%94%9F%E3%81%AB%E3%82%88%E3%82%8B%E6%9C%80%E7%B5%82%E8%AC%9B%E7%BE%A9%EF%BC%88%E5%85%A87%E5%9B%9E%EF%BC%89 Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E8%84%B3%E5%86%85%E7%82%8E%E7%97%87%E3%81%A8%E7%B2%BE%E7%A5%9E%E7%96%BE%E6%82%A3%EF%BD%9E%E3%81%86%E3%81%A4%E7%97%85%E3%82%92%E4%B8%AD%E5%BF%83%E3%81%AB%EF%BD%9E%E3%80%80%E7%B2%BE%E7%A5%9E%E5%8C%BB%E5%AD%A6%E3%82 Anonimnež
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E8%84%B3%E5%86%85%E7%82%8E%E7%97%87%E3%81%A8%E7%B2%BE%E7%A5%9E%E7%96%BE%E6%82%A3%EF%BD%9E%E3%81%86%E3%81%A4%E7%97%85%E3%82%92%E4%B8%AD%E5%BF%83%E3%81%AB%EF%BD%9E%E3%80%80%E7%B2%BE%E7%A5%9E%E5%8C%BB%E5%AD%A6%E3%82 Anonimnež
Newsletter opened Opened Anonimnež
Newsletter opened Opened Anonimnež
Newsletter sent Newsletter Test sent to:AYTK@lundbeck.com Anonimnež
Newsletter opened Opened Anonimnež
Newsletter sent Newsletter Test sent to:AYTK@lundbeck.com Anonimnež
Newsletter opened Opened Anonimnež
Newsletter opened Opened Anonimnež
Newsletter opened Opened Anonimnež
Newsletter clicked Clicked https://brazil.progress.im/pt-br/content/novos-medicamentos-com-anticorpos-monoclonais-t%C3%AAm-como-alvo-cgrp-e-seus-receptores Novos medicamentos têm como alvo a CGRP e seus receptores Anonimnež
Newsletter opened Opened Atualize-se com a Progress in Mind Brazil Anonimnež
Newsletter opened Opened Apoio à saúde mental em tempos de crise Anonimnež
Newsletter opened Opened Novos medicamentos têm como alvo a CGRP e seus receptores Anonimnež
Newsletter opened Opened A disfunção sináptica como fator fisiopatológico chave na esquizofrenia Anonimnež
Newsletter opened Opened Highlight CINP 2021 | O conceito de "engajamento com a vida" como meta de tratamento na esquizofrenia Anonimnež
Newsletter opened Opened Convite Masterclass em Transtorno Depressivo Maior - Webinar Internacional Anonimnež
Newsletter opened Opened Convite Masterclass em Transtorno Depressivo Maior - Webinar Internacional Anonimnež